Organization (Academic)
University of Konstanz
ClinicalTrials.gov lists University of Konstanz as lead sponsor of 51 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo http://www.corporate-design.uni-konstanz.de/, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers University of Konstanz: 51 lead-sponsored trials and 1 legal-entity registration.
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stress Disorders, Post-Traumatic | 32 |
| Substance-Related Disorders | 6 |
| Alcoholism | 5 |
| Schizophrenia | 4 |
| Cognitive Dysfunction | 3 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 5 |
| 2019 | 1 |
| 2018 | 6 |
| 2017 | 6 |
| 2016 | 2 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: none of the 51 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 36% hit target (n=14) | 33% on time (n=15) |
Journals published in (44)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC psychiatry | 5 |
| BMC public health | 4 |
| Behaviour research and therapy | 3 |
| European journal of psychotraumatology | 3 |
| Journal of Alzheimer's disease : JAD | 3 |
Showing 5 of 44 journals.
Latest dated events (65)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 65 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| PDS5A | Trial collaborator | Named in trial inclusion criteria |
| PTGDS | Trial collaborator | Named in trial inclusion criteria |
| SLC26A4 | Trial collaborator | Named in trial inclusion criteria |
| PDS5A | Trial collaborator | Mentioned in trial text |
| PTGDS | Trial collaborator | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Biomarkers this organization publishes on (82)
Shown in this order: most publications first.
Showing 5 of 82 biomarkers.
On Scientist.com
University of Konstanz is listed as a research supplier in the Scientist.com network.
Service areas
Univ. of Konstanz, Molecular Genetics specializes in the research of the processes of mitosis and meiosis.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and clia clinical laboratory certificates.
Work with Univ. of Konstanz, Molecular Genetics on Scientist.com
For prices, more details, or to contact Univ. of Konstanz, Molecular Genetics, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.